NCT04927884 2024-06-12A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior TherapiesImmunityBio, Inc.Phase 1/2 Terminated3 enrolled 9 charts